Atorvastatina L.B.A.

Atorvastatina L.B.A. may be available in the countries listed below.

Ingredient matches for Atorvastatina L.B.A.

Atorvastatin

Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Atorvastatina L.B.A. in the following countries:

• Argentina

International Drug Name Search

Bromhexina Lafedar

Bromhexina Lafedar may be available in the countries listed below.

Ingredient matches for Bromhexina Lafedar

Bromhexine

Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Bromhexina Lafedar in the following countries:

• Argentina

International Drug Name Search

Oxybutynin-Generics

Oxybutynin-Generics may be available in the countries listed below.

Ingredient matches for Oxybutynin-Generics

Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Oxybutynin-Generics in the following countries:

• Luxembourg

International Drug Name Search

Jalyn

Jalyn is a brand name of dutasteride/tamsulosin, approved by the FDA in the following formulation(s):

JALYN (dutasteride; tamsulosin hydrochloride - capsule; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 14, 2010
  
  Strength(s): 0.5MG;0.4MG ^[RLD]

Has a generic version of Jalyn been approved?

No. There is currently no therapeutically equivalent version of Jalyn available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jalyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Androstenone derivative
  Patent 5,565,467
  Issued: October 15, 1996
  Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • November 20, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Androstenone derivative
  Patent 5,846,976
  Issued: December 8, 1998
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
  
  



• 
  Androstenones
  Patent 5,998,427
  Issued: December 7, 1999
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Jalyn Consumer Information (Drugs.com)
• Jalyn Consumer Information (Wolters Kluwer)
• Jalyn Consumer Information (Cerner Multum)
• Jalyn Advanced Consumer Information (Micromedex)
• Dutasteride/Tamsulosin Consumer Information (Wolters Kluwer)
• Dutasteride and tamsulosin Consumer Information (Cerner Multum)
• Dutasteride and tamsulosin Advanced Consumer Information (Micromedex)

Lisinopril Labesfal

Lisinopril Labesfal may be available in the countries listed below.

Ingredient matches for Lisinopril Labesfal

Lisinopril

Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Lisinopril Labesfal in the following countries:

• Portugal

International Drug Name Search

Gemfibrozilo

Gemfibrozilo may be available in the countries listed below.

Ingredient matches for Gemfibrozilo

Gemfibrozil

Gemfibrozil is reported as an ingredient of Gemfibrozilo in the following countries:

• Chile


• Colombia


• Ecuador

International Drug Name Search

Cefaclor AL

Cefaclor AL may be available in the countries listed below.

Ingredient matches for Cefaclor AL

Cefaclor

Cefaclor monohydrate (a derivative of Cefaclor) is reported as an ingredient of Cefaclor AL in the following countries:

• Czech Republic


• Germany

International Drug Name Search

Plenum

Plenum may be available in the countries listed below.

Ingredient matches for Plenum

Guaifenesin

Guaifenesin is reported as an ingredient of Plenum in the following countries:

• Argentina

International Drug Name Search

Polocaine with Levonordefrin

Ingredient matches for Polocaine with Levonordefrin

Corbadrine

Corbadrine is reported as an ingredient of Polocaine with Levonordefrin in the following countries:

• United States

Mepivacaine

Mepivacaine hydrochloride (a derivative of Mepivacaine) is reported as an ingredient of Polocaine with Levonordefrin in the following countries:

• United States

International Drug Name Search

Bartolium

Bartolium may be available in the countries listed below.

Ingredient matches for Bartolium

Flunarizine

Flunarizine is reported as an ingredient of Bartolium in the following countries:

• Indonesia

International Drug Name Search

Omitac

Omitac may be available in the countries listed below.

Ingredient matches for Omitac

Omeprazole

Omeprazole is reported as an ingredient of Omitac in the following countries:

• Bangladesh

International Drug Name Search

Spiramycin Bidiphar

Spiramycin Bidiphar may be available in the countries listed below.

Ingredient matches for Spiramycin Bidiphar

Spiramycin

Spiramycin is reported as an ingredient of Spiramycin Bidiphar in the following countries:

• Vietnam

International Drug Name Search

Allertyn

Allertyn may be available in the countries listed below.

Ingredient matches for Allertyn

Loratadine

Loratadine is reported as an ingredient of Allertyn in the following countries:

• Hong Kong


• Singapore

International Drug Name Search

Orthoclone

Orthoclone may be available in the countries listed below.

Ingredient matches for Orthoclone

Muromonab-Cd3

Muromonab-CD3 is reported as an ingredient of Orthoclone in the following countries:

• Australia


• Belgium


• Costa Rica


• Dominican Republic


• El Salvador


• Finland


• Germany


• Greece


• Guatemala


• Honduras


• Israel


• Italy


• Japan


• Nicaragua


• Panama

International Drug Name Search